诺华制药 NVS 深 沪
已收盘 09-25 16:00:00 美东时间
145.46
+1.890
+1.32%
华盛通- 最 高145.51
- 今 开144.57
- 成交量 116.57万股
- 最 低 144.0003
- 昨 收 143.57
- 总市值 2.76亿
- 52周最高 167.3788
- 市盈率 静 20.23
- 换手率 0.01%
- 52周最低 118.4888
- 委 比 -86.81%
- 总股本 0.02亿
- 历史最高 167.3788
- 量 比 0.60
- 振 幅 1.05%
- 历史最低 3.8803
- 每 手 1
- 风险率 12.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股异动 | 医药股逆市走高 礼来(LLY.US)涨近4%
周四，美股医药股逆市走高，礼来(LLY.US)涨近4%，市值约1.12万亿美元，辉瑞(PFE.US)涨超2%，默沙东(MRK.US)、强生(JNJ.US)涨近...
09-24 22:35
美股医药股逆市走高，礼来涨近4%，辉瑞涨超2%
每经AI快讯，9月24日，美股医药股逆市走高，礼来涨近4%，辉瑞涨超2%，默沙东、强生涨近2%，诺华制药、诺和诺德涨超1%。AI医疗概念股Tempus AI涨近...
09-24 22:20
A Federal Judge In Manhattan Ruled For Novartis On Wednesday Against Allegations That It Misused One Of Its Patents To Maintain Its Exclusivity On Its Blockbuster Heart-Failure Drug Entresto
A Federal Judge In Manhattan Ruled For Novartis On Wednesday Against Allegations That It Misused One Of Its Patents To Maintain Its Exclusivity On Its Blockbuster Heart-Failure Drug Entresto
09-24 03:02
重磅！安进CD40L自免药物III期成功
（来源：药研网） 9月22日，安进公布dazodalibep治疗中重度系统性干燥综合征的III期OASIZ 301研究达到主要终点：第48周显示出统计学显著且临...
09-23 17:46
HSBC Remains a Buy on Novartis AG (NOVN)
HSBC analyst Rajesh Kumar maintained a Buy rating on Novartis AG today and set ...
09-23 13:55
9亿美元！博锐创合与诺华就放射性偶联药物达成许可协议
（来源：求实药社） 9月22日，苏州博锐创合医药有限公司（以下简称“博锐创合”）宣布公司与诺华（Novartis）就一项临床前放射性配体疗法达成全球独家许可...
09-23 12:02
Lantheus gains approval of Bravnesta, generic competitor to Lutathera
The US FDA has granted final approval to Lantheus Holdings' (LNTH) Bravnesta (lutetium Lu 177 dotatate), a bioequivalent to Novartis' (NVS) radiopharmaceutical to Lutathera. Bravnesta is used for the ...
09-22 22:39
Amgen gains on late-stage trial win for Sjögren's disease therapy
Amgen (AMGN) traded higher in the premarket on Tuesday after the company announced a late-stage trial win for dazodalibep, its experimental therapy for an autoimmune condition called Sjögren's disease...
09-22 21:22
Lantheus withdraws, resubmits HSR filing for Curium acquisition
Lantheus Holdings (LNTH) said it has withdrawn and refiled its Hart-Scott-Rodino (HSR) Act pre-merger notification regarding its $8B acquisition of Curium. The withdrawal, done on Sept. 17, was done "...
09-22 05:35
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
https://www.bloomberg.com/news/articles/2026-09-16/novartis-experimental-drug-for-als-fails-in-another-pipeline-hit
09-16 23:39
